Orient Bio
Provider of research models, biological materials and preclinical research services. Operates breeding and supply systems for laboratory animals including non-human primates, runs GLP-compliant nonclinical testing and offers disease model development and CRO support for preclinical biopharmaceutical research. In January 2022 the company sold its U.S. primate center (OBRC) to a U.S. CRO, receiving proceeds reported as 657 billion KRW and acquiring part of the consideration as equity in the buyer.
Industries
Nr. of Employees
medium (51-250)
Orient Bio
Seongnam, Kyonggi-do, South Korea, Asia
Products
Reagents
Research reagents supplied to laboratories.
Bio supplies
Laboratory consumables and supplies for research use.
Laboratory equipment
Equipment for laboratory and research facility use.
Reagents
Research reagents supplied to laboratories.
Bio supplies
Laboratory consumables and supplies for research use.
Laboratory equipment
Equipment for laboratory and research facility use.
Services
Design, breeding and supply of research animal models and related model development services for preclinical studies.
GLP-accredited safety testing services including repeated-dose toxicity, genotoxicity assays and toxicokinetic analysis.
End-to-end preclinical study support using non-human primates, including behavioral analysis and other specialized NHP research workflows.
Design, breeding and supply of research animal models and related model development services for preclinical studies.
GLP-accredited safety testing services including repeated-dose toxicity, genotoxicity assays and toxicokinetic analysis.
End-to-end preclinical study support using non-human primates, including behavioral analysis and other specialized NHP research workflows.
Expertise Areas
- Nonclinical CRO services with emphasis on non-human primates
- Laboratory animal breeding and colony management
- Disease model development for preclinical studies
- GLP-compliant toxicology and genotoxicity testing
Key Technologies
- GLP-compliant toxicology testing
- Genotoxicity assays (Ames test, chromosomal aberration, micronucleus)
- Toxicokinetic analysis
- Colony management for non-human primates
News & Updates
Profile of the company's role in establishing large-scale non-human primate production and its contribution during the COVID-19 pandemic.
Report on a company volunteer program providing housing environment improvements for elderly residents.
Announcement that the company sold its U.S. primate center (OBRC) to a U.S. CRO (INOTIV) in a transaction reported at a total of 657 billion KRW (613 billion KRW sale price plus 44 billion KRW receivables). Part of the consideration (approximately 275 billion KRW) was received as newly issued shares of the buyer; the transaction note details prior acquisition of OBRC in 2017 and revenue growth at the facility following acquisition.
Obtained additional GLP certification covering repeated-dose toxicity, multiple genotoxicity assays and toxicokinetics for nonclinical testing.
Sold ownership of a U.S. primate breeding/production center (OBRC) and received reported proceeds of 657 billion KRW, with a portion of proceeds taken as equity in the buyer as part of the transaction.
Profile of the company's role in establishing large-scale non-human primate production and its contribution during the COVID-19 pandemic.
Report on a company volunteer program providing housing environment improvements for elderly residents.
Announcement that the company sold its U.S. primate center (OBRC) to a U.S. CRO (INOTIV) in a transaction reported at a total of 657 billion KRW (613 billion KRW sale price plus 44 billion KRW receivables). Part of the consideration (approximately 275 billion KRW) was received as newly issued shares of the buyer; the transaction note details prior acquisition of OBRC in 2017 and revenue growth at the facility following acquisition.
Obtained additional GLP certification covering repeated-dose toxicity, multiple genotoxicity assays and toxicokinetics for nonclinical testing.
Sold ownership of a U.S. primate breeding/production center (OBRC) and received reported proceeds of 657 billion KRW, with a portion of proceeds taken as equity in the buyer as part of the transaction.